Atai Life Sciences N.V. (NASDAQ:ATAI) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Stephen Bardin - Chief Financial Officer Florian Brand - Chief Executive Officer and Co-Founder Srini Rao - Chief Scientific Officer and Co-Founder Conference Call Participants Andrew Tsai - Jefferies Ritu Baral - Cowen Stephen Bardin Hi, everyone and welcome to the Atai Life Sciences Third Quarter Earnings Call. I am Stephen Bardin, CFO of Atai and I am very pleased to have you with us. ...

Atai Life Sciences N.V. (NASDAQ:ATAI) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants Greg Weaver – Chief Financial Officer Stephen Bardin – Deputy Chief Financial Officer Florian Brand – Chief Executive Officer Srini Rao – Chief Scientific Officer Conference Call Participants Judah Frommer – Credit Suisse Andrew Tsai – Jefferies LLC Greg Weaver Hi, everyone. Welcome and thanks for joining us for the Atai Second Quarter Earnings Call. I’m Greg Weaver, CFO of Atai Life Scienc ...

Financial Data and Key Metrics Changes - The total cash used in Q1 2022 was $27 million, with a cash position of $335 million at the end of the quarter, providing a runway into 2024 [3] Business Line Data and Key Metrics Changes - The company is focused on developing a diverse pipeline in neuropsychiatry, with a unique model aimed at de-risking assets and providing multiple shots on goal [8][9] Market Data and Key Metrics Changes - The biotech equity markets are currently turbulent, with the XBI biotech index trading below levels seen five years ago, presenting both challenges and opportunities for investment [6][7] Company Strategy and Development Direction - The company aims to leverage its strong cash position to acquire complementary assets and continue its pipeline development, particularly in the neuropsychiatry space, which has seen little innovation [7][9] - The strategy includes integrating digital therapeutics with pharmacological agents to enhance treatment efficacy for mental health disorders [11][12] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the current challenges in the biotech market but expresses optimism about the company's ability to weather the storm due to its strong treasury and disciplined cash management [46][47] - The company is focused on reaching key clinical milestones and remains optimistic about both near-term and long-term prospects [47] Other Important Information - The company has over a thousand licensed clinics in the U.S. that can administer SPRAVATO, which may serve as a foundation for its own product rollout [17] Q&A Session Summary Question: How is atai navigating the turbulent biotech equity markets? - Management sees the current market conditions as an opportunity to invest in undervalued biotech assets and remains active in screening for new opportunities [6][9] Question: How does the digital therapeutics initiative fit into the company's strategy? - The digital therapeutics are integral to the treatment of mental health disorders, and the company is committed to fully funding this unit to support clinical trials [11][12] Question: What lessons have been learned from the SPRAVATO launch? - The company aims to differentiate its product from SPRAVATO by focusing on at-home use and leveraging existing clinic infrastructure [16][17] Question: What are the key takeaways from COMPASS Pathways' Phase 2b data? - Management highlighted the rapidity of onset and durability of effect as critical factors and expressed interest in COMPASS's Phase 3 plans [24][25] Question: How does the company view the role of GABAergic mechanisms in anxiety disorders? - The company believes its GABAergic candidate offers a unique mechanism that may provide a better safety profile compared to traditional benzodiazepines [36][38]

atai Life Sciences N.V. (NASDAQ:ATAI) Q4 2021 Results Earnings Conference Call March 30, 2022 8:30 AM ET Company Participants Colin Keeler - Manager, Corporate Finance Christian Angermayer - Founder and Chairman Florian Brand - Co-Founder, Chief Executive Officer and Managing Director Srinivas Rao - Co-Founder and Chief Scientific Officer Greg Weaver - Chief Financial Officer and Managing Director Conference Call Participants Andrew Tsai - Jefferies LLC Neena Bitritto-Garg - Citi Investment Research (US) Ch ...